WFG Advisors LP cut its position in Eli Lilly and Company (NYSE:LLY) by 17.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,524 shares of the company’s stock after selling 1,189 shares during the period. WFG Advisors LP’s holdings in Eli Lilly and were worth $465,000 at the end of the most recent quarter.
Several other hedge funds have also added to or reduced their stakes in the company. Joel Isaacson & Co. LLC increased its position in Eli Lilly and by 1.5% in the first quarter. Joel Isaacson & Co. LLC now owns 3,364 shares of the company’s stock valued at $283,000 after buying an additional 50 shares during the period. Nisa Investment Advisors LLC increased its position in Eli Lilly and by 3.1% in the first quarter. Nisa Investment Advisors LLC now owns 324,377 shares of the company’s stock valued at $27,280,000 after buying an additional 9,680 shares during the period. Franklin Street Advisors Inc. NC purchased a new position in Eli Lilly and during the first quarter valued at $320,000. Washington Trust Bank increased its position in Eli Lilly and by 92.8% in the first quarter. Washington Trust Bank now owns 10,369 shares of the company’s stock valued at $872,000 after buying an additional 4,990 shares during the period. Finally, Bollard Group LLC increased its position in Eli Lilly and by 2.7% in the first quarter. Bollard Group LLC now owns 313,974 shares of the company’s stock valued at $26,408,000 after buying an additional 8,153 shares during the period. Institutional investors and hedge funds own 75.61% of the company’s stock.
Eli Lilly and Company (NYSE:LLY) traded down 0.47% on Friday, hitting $81.15. The stock had a trading volume of 2,445,840 shares. The company has a market capitalization of $85.61 billion, a price-to-earnings ratio of 35.11 and a beta of 0.34. Eli Lilly and Company has a 52 week low of $64.18 and a 52 week high of $86.72. The firm has a 50-day moving average of $83.00 and a 200 day moving average of $81.69.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The company had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. During the same quarter in the previous year, the company posted $0.86 earnings per share. Eli Lilly and’s revenue was up 7.8% compared to the same quarter last year. On average, analysts predict that Eli Lilly and Company will post $4.16 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th will be paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.56%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and’s dividend payout ratio (DPR) is 90.04%.
TRADEMARK VIOLATION NOTICE: “WFG Advisors LP Has $465,000 Position in Eli Lilly and Company (LLY)” was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/08/11/wfg-advisors-lp-reduces-stake-in-eli-lilly-and-company-lly-updated.html.
A number of brokerages recently commented on LLY. Berenberg Bank reaffirmed a “buy” rating and set a $98.00 price objective on shares of Eli Lilly and in a research report on Friday, August 4th. BMO Capital Markets restated a “sell” rating and issued a $73.00 price objective on shares of Eli Lilly and in a research note on Friday, August 4th. TheStreet upgraded shares of Eli Lilly and from a “c+” rating to a “b+” rating in a research note on Tuesday, July 25th. UBS AG cut shares of Eli Lilly and to a “hold” rating and set a $85.00 target price for the company. in a research note on Wednesday, July 26th. Finally, Oppenheimer Holdings, Inc. lowered shares of Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 price target on the stock. in a report on Wednesday, July 26th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $88.27.
In related news, major shareholder Lilly Endowment Inc sold 220,000 shares of the business’s stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $83.09, for a total value of $18,279,800.00. Following the sale, the insider now directly owns 124,049,283 shares in the company, valued at $10,307,254,924.47. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Michael J. Harrington sold 22,833 shares of the company’s stock in a transaction that occurred on Friday, June 9th. The shares were sold at an average price of $79.97, for a total value of $1,825,955.01. Following the sale, the vice president now owns 62,056 shares in the company, valued at $4,962,618.32. The disclosure for this sale can be found here. In the last ninety days, insiders sold 669,733 shares of company stock valued at $55,845,287. Corporate insiders own 0.20% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
What are top analysts saying about Eli Lilly and Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eli Lilly and Company and related companies.